|
|
||||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLE |
1 Third Division of Infective Diseases, D. Cotugno Hospital, Naples 80100, Italy
2 Department of Biochemistry and Biophysic "F. Cedrangolo", Section of Anatomic Pathology, Second University of Naples, Naples 80100, Italy
3 Section of Oncology, Campus BioMedico University, Rome 00100, Italy
4 Department of Thoracic Surgery, Second University of Naples
5 Department of Thoracic Surgery, Tor Vergata University, Rome 00100, Italy
6 A.O. "L. Spallanzani", Rome 00100, Italy
7 Department of Cardio-Thoracic Surgery, University of Vienna, Vienna 1008, Austria
Correspondence to:
Dr A Baldi
Via G. Orsi 25, 80128 Naples, Italy; alfonsobaldi{at}tiscali.it
Background/Aims: Abnormalities of the proteins involved in cell cycle checkpoints are extremely common among almost all neoplasms. This study aimed to investigate the expression of four components of the cell cycle machineryp21, p16, p53, and proliferating cell nuclear antigen (PCNA)in non-small cell lung cancer (NSCLC).
Methods: The expression of p21, p16, p53, and PCNA was examined in 68 well characterised NSCLC specimens using immunohistochemistry. The coregulation of these proteins and their influence on survival were analysed using both univariate and multivariate analyses.
Results: By univariate analysis, the expression of all the proteins examined, except for PCNA, was significantly correlated with survival. In multivariate analysis, the only immunohistochemical parameter able to influence overall survival was p16, confirming the hypothesis that the RBp16 tumour suppressor pathway is inactivated in most lung cancer samples. Finally, the group of patients with NSCLC who were negative for both p21 and p16 had a significantly shorter overall survival.
Conclusions: These results suggest that loss of control of cell cycle checkpoints is a common occurrence in lung cancers, and support the idea that functional cooperation between different cell cycle inhibitor proteins constitutes another level of regulation in cell growth control and tumour suppression.
Abbreviations: ALND, axillary lymph node dissection; H&E, haematoxylin and eosin; LVI, lymphovascular invasion; SLN, sentinel lymph node
This article has been cited by other articles:
![]() |
S Mohamed, K Yasufuku, T Nakajima, K Hiroshima, R Kubo, A Iyoda, S Yoshida, M Suzuki, Y Sekine, K Shibuya, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response Thorax, July 1, 2008; 63(7): 642 - 647. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhang, X. Jin, F. Wang, S. Wang, C. Deng, Z. Gao, and C. Guo Combined Prognostic Value of Both RelA and I{kappa}B-{alpha} Expression in Human Non Small Cell Lung Cancer Ann. Surg. Oncol., December 1, 2007; 14(12): 3581 - 3592. [Abstract] [Full Text] [PDF] |
||||
![]() |
C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Pajares, I. Zudaire, M. D. Lozano, J. Agorreta, G. Bastarrika, W. Torre, A. Remirez, R. Pio, J. J. Zulueta, and L. M. Montuenga Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 373 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Jiang, N. P. Caraway, B. Nebiyou Bekele, H.-Z. Zhang, A. Khanna, H. Wang, R. Li, R. L. Fernandez, T. M. Zaidi, D. A. Johnston, et al. Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5417 - 5424. [Abstract] [Full Text] [PDF] |
||||
![]() |
V Esposito, A Baldi, A De Luca, G Tonini, B Vincenzi, D Santini, P Persichetti, A Mancini, G Citro, F Baldi, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer J. Clin. Pathol., July 1, 2005; 58(7): 734 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Singhal, A. Vachani, D. Antin-Ozerkis, L. R. Kaiser, and S. M. Albelda Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non-Small Cell Lung Cancer: A Review Clin. Cancer Res., June 1, 2005; 11(11): 3974 - 3986. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |